Results 21 to 30 of about 14,200 (285)
Development and Optimization of RP-UHPLC Method for Mesalamine Through QbD Approach
Dhaka University Journal of Pharmaceutical Sciences, 2022 The current study aimed at developing and optimizing a prompt, simple and efficient RP-UHPLC method based on Quality by Design (QbD) for analyzing mesalamine.
Diponkor Kumar Shill +4 more
openalex +3 more sources
Drug-Induced Intersticial Nephritis. Clinical Case
Acta Medica Lituanica, 2021 5-Aminosalicylic acid (5-ASA) preparations are widely used in the treatment of inflammatory bowel diseases. The most commonly used medicine is mesalamine. Overall, it is a very safe drug with few side effects.
Paulina Tekoriutė +2 more
doaj +1 more source
Adalimumab as a Potential Therapeutic Option for Metastatic Crohn's Disease With Genital Lesions and Edema: A Case Report. [PDF]
Clin Case RepABSTRACT Metastatic Crohn's disease (MCD) is a rare and complex extraintestinal manifestation of Crohn's disease (CD) that often profoundly affects patients' quality of life. This report presents a meticulously detailed case of a 12‐year‐old Iranian girl with persistent labial swelling and genital lesions, later diagnosed as MCD.
Haghshenas H +4 more
europepmc +2 more sources
Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis. [PDF]
PLoS ONE, 2018 Mesalamine is commonly used to treat ulcerative colitis (UC). Although mesalamine acts topically, in vitro data suggest that intracellular transport is required for its beneficial effect.
Christopher J Moran +5 more
doaj +1 more source
Cureus, 2023 To keep inflammatory bowel disease (IBD) in remission, mesalamine is frequently utilized. It primarily targets the inflammatory response and lowers prostaglandin and leukotriene synthesis. It can be applied topically, orally, or as a suppository.
Ahtshamullah Chaudhry +4 more
semanticscholar +1 more source
Electroanalytical Overview: The Sensing of Mesalamine (5-Aminosalicylic Acid)
ACS Measurement Science Au, 2023 Mesalamine, known as 5-aminosalicylic acid, is a medication used primarily in the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
R. Crapnell +2 more
semanticscholar +1 more source
Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review
Cureus, 2023 Ulcerative colitis (UC) management has changed significantly in the past decade. The goal is to treat the symptoms, aid tissue healing, and change the disease course to improve future outcomes.
Yurianna Santos, Arturo P Jaramillo
semanticscholar +1 more source
RSC Advances, 2023 In the present study, mesalamine-functionalized on magnetic nanoparticles (mesalamine/GPTMS@SiO2@Fe3O4) is fabricated as an efficient and magnetically recoverable nanocatalyst.
Mahdiyeh Partovi +4 more
semanticscholar +1 more source
Case Reports in Gastroenterology, 2011 Mesalamine has been used as the first-line therapy for the treatment of ulcerative colitis (UC) because of its efficacy and fewer side effects. However, earlier study showed that mesalamine occasionally causes diarrhea.
Yuichi Shimodate +5 more
doaj +1 more source
Use of new, once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis. Is there anything new under the sun? [PDF]
, 2009 5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine.
Lakatos, Péter László
core +2 more sources